SCHEMBL9596755

SCHEMBL9596755

COc1cc(C)cc(CO)c1CO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 6/20 0.48
▸ PDE4B Q07343 6/20 0.48
▸ PDE4C Q08493 6/20 0.48
▸ PDE4D Q08499 6/20 0.48
▸ ACHE P22303 2/20 0.45
▸ PDE5A O76074 5/20 0.42
▸ PDE3B Q13370 5/20 0.42
▸ PDE3A Q14432 5/20 0.42
▸ PDE1A P54750 4/20 0.42
▸ PDE1B Q01064 4/20 0.42
▸ PDE1C Q14123 4/20 0.42
▸ PDCD1 Q15116 1/20 0.39
▸ CD274 Q9NZQ7 1/20 0.39
▸ ERN1 O75460 1/20 0.38
▸ FNTA P49354 1/20 0.38
▸ FNTB P49356 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ DPP4 P27487 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1225856 0.82 ACHE (0.46) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL12622553 0.80 ALDH1A1 (0.45) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL2621002 0.80 ERN1 (0.50) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL10064029 0.80 ACHE (0.61) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL14666158 0.80 MAPT (0.50) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL18362599 0.80 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL12954538 0.78 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL15725791 0.78 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL15679419 0.78 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL9447252 0.78 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170001958-A1 INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-05 — — US disclosed
US-9493439-B1 Proteasome inhibitors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-11-15 — — US disclosed
US-8883809-B2 Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-11-11 — — US disclosed
US-20120283439-A1 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Redearch (IN) 2012-11-08 — — US disclosed
US-7381842-B2 Oxime ester photoinitiators CIBA SPECIALTY CHEMICALS CORPORATION (US) 2008-06-03 — — US disclosed
WO-1993009113-A1 2-((IMIDAZOL-2-YL)METHYL)-ISOINDOLE DERIVATIVES AS ALPHA-2-ADRENOCEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1993-05-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001958-A1 INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF PDK4, PDK2, PDK3 PDE4A 857/4885PDE4B 867/4885PDE4C 1040/4885
US-20120283439-A1 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF NDUFAF1, TOP1, COX4I1 PDE4A 1600/4885PDE4B 1335/4885PDE4C 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback